Skip to main content

Table 3 Incidence of primary endpoint and each component according to the median of GA

From: Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention

 

Total population (n = 2247)

Lower GA (≤ 14.4%, n = 1133)

Higher GA (> 14.4%, n = 1114)

P value

MACCE, n (%)

547 (24.3)

205 (18.1)

342 (30.7)

< 0.001

All-cause death, n (%)

36 (1.6)

10 (0.9)

26 (2.3)

0.006

Non-fatal MI, n (%)

112 (5.0)

40 (3.5)

72 (6.5)

0.001

Non-fatal ischemic stroke, n (%)

45 (2.0)

22 (1.9)

23 (2.1)

0.835

Ischemia-driven revascularization, n (%)

354 (15.8)

133 (11.7)

221 (19.8)

< 0.001

  1. GA glycated albumin, MACCE major adverse cardio-cerebral events, MI myocardial infarction